Patents by Inventor Alan D. Martin
Alan D. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11896672Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: GrantFiled: April 11, 2017Date of Patent: February 13, 2024Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Richard J. Holland, Alan D. Martin, Mark Wood
-
Publication number: 20230165973Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: August 31, 2022Publication date: June 1, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20230110295Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: ApplicationFiled: June 30, 2022Publication date: April 13, 2023Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
-
Publication number: 20220387600Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to treat certain diseases, such as liver fibrosis, e.g., in the setting of NASH or ASH.Type: ApplicationFiled: December 7, 2020Publication date: December 8, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Richard J. HOLLAND, Mark WOOD, Alan D. MARTIN, Christine ESAU, Margrit SCHWARZ, Xin YE, Alice Hoy Lam LI, Christopher Justin PASETKA, David CROWE, Steven TYLER
-
Publication number: 20220288214Abstract: Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. He conjugates are useful to treat certain diseases, such as acromegaly.Type: ApplicationFiled: October 23, 2020Publication date: September 15, 2022Applicant: GENEVANT SCIENCES GMBHInventors: Drew KONDRATOWICZ, James HEYES, Richard J. HOLLAND, Christine ESAU, Kevin MCCLINTOCK, Christopher Justin PASETKA, Mark WOOD, Alan D. MARTIN, Margrit SCHWARZ, David CROWE, Steven TYLER
-
Patent number: 11427823Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: GrantFiled: April 10, 2018Date of Patent: August 30, 2022Assignee: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Richard J. Holland, Adam Judge, Amy C. H. Lee, Alan D. Martin, Nicholas Michael Snead, Emily P. Thi, Mark Wood, Xin Ye
-
Publication number: 20220168222Abstract: The invention provides lipid nanoparticles and formulations containing lipid nanoparticles.Type: ApplicationFiled: April 24, 2020Publication date: June 2, 2022Applicant: GENEVANT SCIENCES GMBHInventors: James HEYES, Adam JUDGE, Kieu Mong LAM, Alan D. MARTIN
-
Publication number: 20220001029Abstract: The invention provides certain specific lipid nanoparticles comprising: (a) one or more nucleic acid molecules; (b) cholesterol; (c) DSPC; (d) PEG-C-DMA; and (b) a cationic lipid of formula CL1 or CL2, and pharmaceutical compositions comprising the lipid nanoparticles. The lipid nanoparticles and pharmaceutical compositions are particularly useful for delivering a nucleic acid to a patient (e.g. a human) or to a cell.Type: ApplicationFiled: November 8, 2019Publication date: January 6, 2022Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: Kieu Mong LAM, Alan D. MARTIN, Petra SCHREINER
-
Publication number: 20200407724Abstract: The invention provides certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic double stranded siRNA to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: ApplicationFiled: April 10, 2018Publication date: December 31, 2020Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Richard J. HOLLAND, Adam JUDGE, Amy C. H. LEE, Alan D. MARTIN, Nicholas Michael SNEAD, Emily P. THI, Mark WOOD, Xin YE
-
Publication number: 20200297870Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: February 24, 2020Publication date: September 24, 2020Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20190160176Abstract: The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).Type: ApplicationFiled: April 11, 2017Publication date: May 30, 2019Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James HEYES, Richard J. HOLLAND, Alan D. MARTIN, Mark WOOD
-
Publication number: 20190106379Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: ApplicationFiled: August 20, 2018Publication date: April 11, 2019Applicant: ARBUTUS BIOPHARMA CORPORATIONInventors: James Heyes, Alan D. Martin, Mark Wood
-
Publication number: 20160256567Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: May 12, 2016Publication date: September 8, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20160256568Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provided cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: May 12, 2016Publication date: September 8, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Publication number: 20160151284Abstract: The present invention provides compositions comprising mRNA molecules encapsulated within lipid particles. The lipid particles comprise a cationic lipid, a non-cationic lipid, and an mRNA molecule that is encapsulated within the lipid particle. The compositions are useful, for example, to introduce the mRNA molecules into a human subject where they are translated to produce a polypeptide that functions to ameliorate one or more symptoms of a disease. The invention also provides cationic lipids that are useful for preparing the compositions of the invention.Type: ApplicationFiled: July 22, 2014Publication date: June 2, 2016Applicant: PROTIVA BIOTHERAPEUTICS, INC.Inventors: James HEYES, Lorne R. PALMER, Stephen P. REID, Edward D. YAWORSKI, Ian MACLACHLAN, Mark WOOD, Alan D. MARTIN
-
Patent number: 6447309Abstract: An apparatus for suppressing power bus bouncing in a hot-swappable system has been developed. The apparatus includes a connection module with three interior pins for: the power return; the power supply; and the system ground. The system ground pin is shorter than the other two so that it makes contact with the power bus after the bouncing from the return and supply pins has subsided.Type: GrantFiled: December 12, 2000Date of Patent: September 10, 2002Assignee: Sun Microsystems, Inc.Inventors: Han Y. Ko, Robert C. Cyphers, Tomonori Hirai, Keith Y. Oka, Alan D. Martin
-
Publication number: 20020072259Abstract: An apparatus for suppressing power bus bouncing in a hot-swappable system has been developed. The apparatus includes a connection module with three interior pins for: the power return; the power supply; and the system ground. The system ground pin is shorter than the other two so that it makes contact with the power bus after the bouncing from the return and supply pins has subsided.Type: ApplicationFiled: December 12, 2000Publication date: June 13, 2002Inventors: Han Y. Ko, Robert C. Cyphers, Tomonori Hirai, Keith Y. Oka, Alan D. Martin
-
Patent number: 5564108Abstract: This apparatus makes use of the existing data collection probe connector on the instrumentation as the port through which the software updates are loaded into the programmable memory devices that are used to store the operational software of the instrumentation. Circuitry is provided in the instrumentation to automatically differentiate between software update data being loaded into the instrumentation and the normal monitoring data that is received from the probe. This is accomplished by the use of probe defining circuitry that is able to differentiate between the standard probe used for data collection purposes and the software update probe that is provided to download software into the programmable memory devices.Type: GrantFiled: May 12, 1995Date of Patent: October 8, 1996Assignee: Ohmeda Inc.Inventors: Scott W. Hunsaker, Stephan Kulik, III, Alan D. Martin, Craig A. Totel
-
Patent number: 4846183Abstract: A pulse oximeter or plethysmographic device utilizes light varying in intensity at a predetermined carrier frequency. A passive resonant circuit having a resonant frequency substantially equal to the carrier frequency is connected between the photodetector and the first amplifier. The resonant circuit serves to suppress spurious DC and low frequency components such as those due to ambient light and ambient light flicker and also to suppress high frequency interference. Because ambient light signals are suppressed, there is no need for dark current correction or restoration. Suppression of ambient light and other interference upstream of the front end amplifier avoids saturation of the amplifier and permits use of a front end amplifier having high gain.Type: GrantFiled: December 2, 1987Date of Patent: July 11, 1989Assignee: The BOC Group, Inc.Inventor: Alan D. Martin
-
Patent number: 4781195Abstract: In photoelectric apparatus such as a pulse oximeter for monitoring a parameter of the blood in a living organism, a dark current correction signal is applied to the input at the preamplifier. The correction signal is substantially equal in magnitude but opposite in sense to the photodetector output during dark intervals when the illumination means of the apparatus is disabled. Because dark current correction is accomplished at the input of the preamplifier, the preamplifier has substantially increased resistance to overloading caused by ambient light and hence may have higher gain.Type: GrantFiled: December 2, 1987Date of Patent: November 1, 1988Assignee: The BOC Group, Inc.Inventor: Alan D. Martin